CSIMarket
 


Acorda Therapeutics Inc   (ACOR)
Other Ticker:  
 

Cumulative Acorda Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

ACOR's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ACOR Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 6.41 % -29.91 % -27.86 % -29.75 % -38.45 %
Y / Y Cash & cash equivalent Growth 56.88 % 9.27 % -5.08 % -17.75 % -42.78 %
Quick Ratio for Trailing Twelve Months Period 0.87 0.8 0.72 0.68 0.66
Total Ranking # 1533 # 1731 # 1965 # 2419 # 2430
Seq. Current Liabilities Growth 55.16 % -13.15 % -12.56 % -9.69 % 2.2 %
Seq. Cash & cash equivalent Growth 28.48 % -16.48 % -19.4 % 81.37 % -10.51 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Acorda Therapeutics Inc Cash & cash equivalent average soared by 56.88% in III. Quarter year on year, faster than Current Liabilities, this led to increase in in Acorda Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period to 0.87, Quick Ratio for Trailing Twelve Months Period remained below Acorda Therapeutics Inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Acorda Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about ACOR
Quick Ratio ACOR in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 144
Sector # 752
S&P 500 # 1666


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
4.96 2.13 0.58
(Sep. 30, 2014)   (Mar 31 2021)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Halozyme Therapeutics Inc   2.38 
Cel sci Corporation  2.37 
Oyster Point Pharma Inc   2.36 
Sangamo Therapeutics Inc   2.35 
Cellectis S a   2.17 
Qiagen N v   2.13 
Logicbio Therapeutics Inc   2.04 
Innate Pharma Sa  2.04 
Biondvax Pharmaceuticals Ltd   2.02 
Fate Therapeutics Inc   1.97 
Bluebird Bio Inc   1.91 
Seagen Inc   1.85 
Moderna Inc   1.78 
Evaxion Biotech A  1.78 
Nanostring Technologies Inc   1.76 
Titan Pharmaceuticals Inc   1.74 
Neurocrine Biosciences Inc   1.68 
Cidara Therapeutics Inc   1.62 
Repligen Corp  1.59 
Adma Biologics Inc   1.58 
Lexeo Therapeutics Inc   1.54 
Freeline Therapeutics Holdings Plc  1.53 
Cargo Therapeutics Inc   1.47 
Bio techne Corp  1.44 
Biocardia Inc  1.42 
Amgen Inc   1.40 
Pluri Inc   1.39 
Meiragtx Holdings Plc  1.33 
Armata Pharmaceuticals Inc   1.32 
Aerie Pharmaceuticals Inc   1.29 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com